今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

三部华语电影入围东京电影节 梁朝伟大师班再添亮点

东京 - 第36届东京国际电影节将于2023年10月在日本东京举行，三部华语电影成功入围主竞赛单元，分别是顾晓刚执导的《草木人间》、高朋执导的《老枪》以及万玛才旦执导的《雪豹》。这是继2022年贾樟柯执导的《山河》入围东京电影节主竞赛单元后，连续两年有华语电影入围该单元。

本届东京电影节主竞赛单元共遴选了15部来自世界各地的优秀影片，其中三部华语电影的入围，不仅体现了东京电影节对华语电影的重视，也彰显了华语电影在国际影坛日益增长的影响力。

值得一提的是，著名华语演员梁朝伟将担任本届东京电影节评审团主席，并将在电影节期间举办大师班活动。梁朝伟作为亚洲电影的代表人物之一，曾主演过众多脍炙人口的电影作品，在国际影坛享有盛誉。他的大师班活动无疑将成为本届东京电影节的一大亮点。

三部入围华语电影各有特色

顾晓刚执导的《草木人间》改编自作家刘慈欣的同名小说，讲述了在未来世界，人类文明遭到毁灭，一群科学家试图寻找拯救世界的办法的故事。该片以宏大的格局和精美的视效，展现了人类与自然的深刻思考。

高朋执导的《老枪》是一部年代剧情片，以1949年为背景，讲述了一位老兵在解放战争胜利后，寻找昔日战友和自己身份的故事。该片以细腻的情感和朴实的笔触，刻画了普通人的精神世界。

万玛才旦执导的《雪豹》是一部藏语电影，讲述了上世纪50年代，一支藏族骑兵部队在雪域高原英勇抗击外敌入侵的故事。该片以壮丽的雪山风光和独特的民族文化，展现了藏族人民的英雄气概。

梁朝伟大师班期待碰撞思想火花

梁朝伟将举办的大师班活动，是本届东京电影节的重要组成部分。梁朝伟将与来自世界各地的电影人分享他的表演经验和对电影的理解，并与观众进行互动交流。相信此次大师班活动将为观众带来宝贵的学习机会，促进电影文化的交流与碰撞。

三部华语电影的入围和梁朝伟大师班的举办，为本届东京电影节增添了浓厚的华语色彩。相信本届东京电影节将为观众呈现更多精彩的电影作品和思想盛宴。